CoChat

Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission

Open access

The DOI matches its Crossref record; 647 of the 647 references it cites were found in a registry or an index; 336 of the 490 sources its claims cite were checked for support.

Overview

CoChat Summary

TL;DR

The 2024 Lancet Commission update adds uncorrected vision impairment and high LDL cholesterol to the 12 previously identified modifiable dementia risk factors, estimating that 14 factors account for 45.3% of dementia PAF. It concludes that risk can be reduced across the lifecourse, while anti-amyloid antibodies show small 18-month effects with uncertain clinical importance and implementation challenges.

Key findings

  • The 14 risk factors account for a weighted PAF of 45.3% (nearly half of dementias theoretically preventable); the new factors are uncorrected vision impairment and high LDL-C, added to less education, hearing impairment, hypertension, smoking, obesity, depression, physical inactivity, diabetes, excessive alcohol, TBI, air pollution, and social isolation.
  • New meta-analyses: hearing loss was associated with HR 1.37 (1.00–1.87, I²=80%, n=666,370) for dementia; depression was associated with RR 2.25 (1.69–2.98, I²=82.8%) at 10–14 years. Hearing aid use was associated with 17% lower dementia risk (0.77–0.90) and 19% lower cognitive decline (0.76–0.87) in 8 cohorts with 126,903 participants.
  • Vision impairment was associated with pooled RR 1.47 (1.36–1.60) for dementia in 14 cohorts (6,204,827 older adults); each 1 mmol/L higher LDL-C was associated with 8% increased all-cause dementia incidence (1.08, 1.03–1.14).
  • Anti-amyloid antibodies: lecanemab reduced worsening by 0.45 CDR-SB points versus placebo at 18 months; donanemab showed iADRS -10.19 versus -13.11. Effects were small, with ARIA, monitoring, and cost concerns. Cholinesterase inhibitors showed modest long-term benefit and lower mortality in observational studies.

Methods

  • International, interdisciplinary commission used a triangulation framework, prioritising systematic reviews/meta-analyses and performing new meta-analyses where needed; commissioners wrote sections, debated, and unanimously agreed on the evidence.
  • New random-effects meta-analyses were performed for hearing loss and depression; PAF calculation incorporated 14 risk factors using the largest recent worldwide meta-analyses for prevalence and relative risks, with the HUNT study (37,000 participants aged ≥45) used to estimate communality/clustering and weighted PAF adjusted for communality.
  • Hearing loss search was updated to March 20, 2023, across PubMed, Ovid Embase, PsycINFO, Web of Science, Cochrane Library, PROSPERO, and Centre for Reviews and Dissemination.

Limitations

  • Stated: most global research is from HICs, with LMICs under-represented; HUNT had lower alcohol abuse prevalence and lacked ethnic diversity; no worldwide LDL-C prevalence estimate existed, so a single cohort estimate was used; new meta-analyses were not pre-registered; air pollution could not be meta-analysed; selection criteria were subjective; risk modification affects populations but does not guarantee any individual avoids dementia.
  • Stated: many associations may be only partly causal; observational evidence and reverse causation are concerns, especially for late-life risk factors and prodromal dementia.
  • Evident from the text: anti-amyloid trials excluded many multimorbid and diverse patients (e.g., only 8% [19/237] of a community-based Mayo Clinic sample with amyloid positivity and MCI/mild dementia would have met lecanemab eligibility), and biomarker studies are largely in White populations, limiting generalisability.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(24)01296-0

Cites

647 of 647 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

238 Valid · 54 Not valid · 106 Not checked · 157 Own results and interpretations

302 more claims · 147 with their cited sources checked

Create a free account to see all 555 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 229
  • Probably not a substantial claim. 48

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

6 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

2 of 2

Cited works that were retracted

Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.

1 of 1

Citations

Cites

1 retracted

Show all 647 references

Cited by

See all 3,860

Metadata

Authors
Livingston, G., Huntley, J., Liu, K. Y., Costafreda, S. G., Selbæk, G., Alladi, S., Ames, D., Banerjee, S., Burns, A., Brayne, C., Fox, N. C., Ferri, C. P., Gitlin, L. N., Howard, R., Kales, H. C., Kivimäki, M., Larson, E. B., Nakasujja, N., Rockwood, K., Samus, Q., Shirai, K., Singh-Manoux, A., Schneider, L. S., Walsh, S., Yao, Y., Sommerlad, A., & Mukadam, N.
Affiliations
  • University College London (GB)
  • University of Exeter (GB)
  • Oslo University Hospital (NO)
  • National Institute of Mental Health and Neurosciences (IN)
  • The University of Melbourne (AU)
  • University of Nottingham (GB)
  • University of Manchester (GB)
  • University of Cambridge (GB)
  • Hospital Alemão Oswaldo Cruz (BR)
  • Drexel University (US)
  • University of California Davis Medical Center (US)
  • University of Washington (US)
  • Makerere University (UG)
  • Dalhousie University (CA)
  • Johns Hopkins University (US)
  • The University of Osaka (JP)
  • University of Southern California (US)
  • Peking University (CN)
Corresponding author
Livingston, Gill
Venue
The Lancet
Publisher
Elsevier BV
Published
2024-08
Volume
404
Issue
10452
Pages
572-628
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W4401164724
Cited by
3,860
References
637
Citations by year
2026: 1901 · 2025: 1762 · 2024: 197
FWCI
1128.86
Type
journal article
Language
en
Open access
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
  • UCL Discovery (University College London) (submittedVersion)
  • Apollo (University of Cambridge) (submittedVersion, cc-by)
  • Työväentutkimus Vuosikirja (submittedVersion)
  • Apollo (cc-by)
Funders
  • Alzheimer's Society
  • National Institute for Health and Care Research
  • University College London
  • University College London Hospitals NHS Foundation Trust
  • Medical Research Council (MR/S021418/1, MR/S011676/1, MR/Y014154/1, MR/R024227/1)
  • Economic and Social Research Council
  • Japan Society for the Promotion of Science (21KK0168, 23K24610)
  • National Institute on Aging (R01AG056477)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Health Professions › Speech and Hearing › Hearing Loss and Rehabilitation
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Keywords
dementia prevention, dementia interventions, dementia care, Alzheimer's disease, mild cognitive impairment, cognitive decline, hearing loss, age-related hearing loss, hearing aids, dementia risk, hazard ratio
MeSH terms
Dementia, Humans

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (prompt extract-v3).

A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. https://app.cochat.ai/papers/10.1016/s0140-6736(24)01296-0
The paper
Livingston, G., Huntley, J., Liu, K. Y., Costafreda, S. G., Selbæk, G., Alladi, S., Ames, D., Banerjee, S., Burns, A., Brayne, C., Fox, N. C., Ferri, C. P., Gitlin, L. N., Howard, R., Kales, H. C., Kivimäki, M., Larson, E. B., Nakasujja, N., Rockwood, K., . . . Mukadam, N. (2024). Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. The Lancet. https://doi.org/10.1016/s0140-6736(24)01296-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.